Development of a broad-host-range phage cocktail for biocontro

Bioengineered Bugs

Volumn 2, Issue 1, 2011, Pages 31-37

  Kelly, David ^a   McAuliffe, Olivia ^b   Paul Ross, R ^b   O'Mahony, Jim ^a   Coffey, Aidan ^a  

^a Ireland   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Adsorption inhibition; Bacteriophage; Restriction modification; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BIOLOGICAL PEST CONTROL; HOST RANGE; NONHUMAN; STAPHYLOCOCCUS AUREUS; METHODOLOGY; PHYSIOLOGY; VIROLOGY;

STAPHYLOCOCCUS AUREUS;

BACTERIOPHAGES; HOST SPECIFICITY; PEST CONTROL, BIOLOGICAL; STAPHYLOCOCCUS AUREUS;

EID: 78751618268     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.2.1.13657     Document Type: Article

References (43)

1. Abhilash M, Vidya A, Jagadevi T. Bacteriophage therapy: A war against antibiotic resistant bacteria. Internet J Alt Med 2009; 7.
2. O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 2005; 71:1836-42.
3. Mann NH. The potential of phages to prevent MRSA infections. Res Microbiol 2008; 159:400-5.
4. Shasha SM, Sharon N, Inbar M. Bacteriophages as antibacterial agents. Harefuah 2004; 143:121-5.
5. Górski, A, Miedzybrodzki R, Borysowski J, Weber- Dabrowska B, Lobocka M, Fortuna W, et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 2009; 10:766-74.
6. O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009; 33:801-19.
7. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005; 11:211-9.
8. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006; 296:5-14.
9. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 2007; 30:118-28.
10. Housby JN, Mann NH. Phage therapy. Drug Discov Today 2009; 14:536-40.
11. O'Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, Ross RP. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting grampositive bacteria with a low G + C content. J Bacteriol 2004; 186:2862-71.
12. Greer GG, Dilts BD. Inability of a bacteriophage pool to control beef spoilage. Int J Food Microbiol 1990; 10:331-42.
13. Hansen VM, Rosenquist H, Baggesen DL, Brown S, Christensen BB. Characterization of Campylobacter phages including analysis of host range by selected Campylobacter Penner serotypes. BMC Microbiol 2007; 18:90.
14. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009; 17:66-72.
15. Yang H, Liang L, Lin S, Jia S. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol 2010; 29:131.
16. Bielke L, Higgins S, Donoghue A, Donoghue D, Hargis BM. Salmonella host range of bacteriophages that infect multiple genera. Poult Sci 2007; 86:2536-40.
17. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 2005; 100:280-7.
18. Abuladze T, Li M, Menetrez MY, Dean T, Senecal A, Sulakvelidze A. Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli and ground beef by Escherichia coli O157:H7. Appl Environ Microbiol 2008; 74:6230-8.
19. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4:4944.
20. Niu YD, Johnson RP, Xu Y, McAllister TA, Sharma R, Louie M, et al. Host range and lytic capability of four bacteriophages against bovine and clinical human isolates of Shiga toxin-producing Escherichia coli O157:H7. J Appl Microbiol 2009; 107:646-56.
21. Kunisaki H, Tanji Y. Intercrossing of phage genomes in a phage cocktail and stable coexistence with Escherichia coli O157:H7 in anaerobic continuous culture. Appl Microbiol Biotechnol 2010; 85:1533-40.
22. Samuels ML, Witmer JA. Statistics for the Life Sciences. Third edition. Pearson Education Inc 2003; 441:686.
23. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 2010; 70:217-48.
24. Hensen SM, Pavicic MJ, Lohuis JA, de Hoog JA, Poutrel B. Location of Staphylococcus aureus within the experimentally infected bovine udder and the expression of capsular polysaccharide type 5 in situ. J Dairy Sci 2000; 83:1966-75.
25. Hogeveen H. Mastitis in dairy production: current knowledge and future solutions. Wageningen academic publishers. The Netherlands 2005; 302-5.
26. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 5:439-43.
27. Service RF. Orphan drugs of the future? Science 2004; 303:1798.
28. Wenzel RP, Bearman G, Edmond MB. Communityacquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control. Int J Antimicrob Agents 2007; 3:210-2.
29. Gupta R, Prasad Y, Efficacy of Polyvalent Bacteriophage P-27/HP to Control Multidrug Resistant Staphylococcus aureus Associated with Human Infections. Curr Microbiol 2010; In press.
30. Monk AB, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: where are we now? Lett Appl Microbiol 2010; 51:363-9.
31. O'Sullivan D, Twomey DP, Coffey A, Hill C, Fitzgerald GF, Ross RP. Novel type I restriction specificities through domain shuffling of HsdS subunits in Lactococcus lactis. Mol Microbiol 2000; 36:866-75.
32. Tock MR, Dryden DT. The biology of restriction and anti-restriction. Curr Opin Microbiol 2005; 8:466-72.
33. Veiga H, Pinho MG. Inactivation of the SauI type I restriction-modification system is not sufficient to generate Staphylococcus aureus strains capable of efficiently accepting foreign DNA. Appl Environ Microbiol 2009; 75:3034-8.
34. Corvaglia AR, François P, Hernandez D, Perron K, Linder P, Schrenzel J. A type III-like restriction endonuclease functions as a major barrier to horizontal gene transfer in clinical Staphylococcus aureus strains. Proc Natl Acad Sci 2010; 107:11954-8.
35. Krüger DH, Bickle TA. Bacteriophage survival: multiple mechanisms for avoiding the deoxyribonucleic acid restriction systems of their hosts. Microbiol Rev 1983; 47:345-60.
36. Sussenbach JS, Monfoort CH, Schiphof R, Stobberingh EE. A restriction endonuclease from Staphylococcus aureus. Nucleic Acids Res 1976; 3:3193-202.
37. Sussenbach JS, Steenbergh PH, Rost JA, van Leeuwen WJ, van Embden JD. A second site-specific restriction endonuclease from Staphylococcus aureus. Nucleic Acids Res 1978; 5:1153-63.
38. Dempsey RM, Carroll D, Kong H, Higgins L, Keane CT, Coleman DC. Sau42I, a BcgI-like restrictionmodifi{ligature}cation system encoded by the Staphylococcus aureus quadruple-converting phage Phi42. Microbiology 2005; 151:1301-11.
39. Sjöström JE, Löfdahl S, Philipson L. Biological characteristics of a type I restriction-modification system in Staphylococcus aureus. J Bacteriol 1978; 133:1144-9.
40. Barnard L, Seaman A. The adsorption of phage by Staphylococcus spp. Gen Virol 1981; 53:189-92.
41. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial disk susceptibility tests; approved standard-9th edition. CLSI document M2-A9 [ISBN 1-56238-586-0]. Pennsylvania USA 2006.
42. O'Flaherty S, Ross RP, Flynn J, Meaney WJ, Fitzgerald GF, Coffey A. Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections. Lett Appl Microbiol 2005; 41:482-6.
43. O'Flaherty S, Coffey A, Meaney WJ, Fitzgerald GF, Ross RP. Inhibition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine milk. Lett Appl Microbiol 2005; 41:274-9.